Wall Street Zen Downgrades Polyrizon (NASDAQ:PLRZ) to Sell

Polyrizon (NASDAQ:PLRZ) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Polyrizon in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Polyrizon Stock Performance

NASDAQ:PLRZ opened at $12.00 on Friday. The stock has a 50-day simple moving average of $13.83 and a 200 day simple moving average of $9.89. Polyrizon has a 52-week low of $2.88 and a 52-week high of $2,235.00.

Polyrizon (NASDAQ:PLRZ) last released its earnings results on Wednesday, March 25th. The company reported $2.81 EPS for the quarter.

Institutional Trading of Polyrizon

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC acquired a new stake in Polyrizon Ltd. (NASDAQ:PLRZ) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned 1.35% of Polyrizon at the end of the most recent reporting period.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.